16639-86-4

Usage

Uses

Used in Organic Synthesis:
L-Alanine, N-(ethoxycarbonyl)is used as a protected amino acid in organic synthesis for the controlled formation of complex organic molecules. The ethoxycarbonyl group ensures that the carboxyl group remains inert during reactions, facilitating the synthesis of desired products without side reactions.
Used in Peptide Synthesis:
In peptide synthesis, L-Alanine, N-(ethoxycarbonyl)is utilized as a protected building block. The protection of the carboxyl group allows for the stepwise assembly of peptide chains without premature reactions, ensuring the correct sequence and structure of the final peptide.
Used in Pharmaceutical Production:
L-Alanine, N-(ethoxycarbonyl)is employed in the production of pharmaceuticals, where its protected form enables the synthesis of drug molecules with specific functionalities. The ethoxycarbonyl group can be selectively removed to yield the desired active pharmaceutical ingredient.
Used in Research and Development:
In the research industry, L-Alanine, N-(ethoxycarbonyl)is used as a versatile compound for exploring new chemical reactions and developing novel organic compounds. Its protected form allows researchers to investigate the reactivity and properties of the amino acid in various chemical contexts.
Overall, L-Alanine, N-(ethoxycarbonyl)is a valuable compound in the fields of organic synthesis, pharmaceutical production, and research, providing a protected form of L-alanine that can be selectively deprotected to achieve the desired molecular structures.

Upstream product

• 56-41-7 L-alanin 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 57859-09-3 Eoc-L-Ala-p-aminobenzoesaeureaethylester 
• 154321-02-5 ethyl <2-(3-bromophenyl)-1(S)-methyl-2-oxoethyl>carbamate 
• 79821-81-1 (S)-2-((ethoxycarbonyl)amino)-1-(4-methoxyphenyl)-1-propanone 
• 107673-69-8 (S)-N-(1-Methyl-2-oxo-4-phenyl-3-butenyl)carbamidsaeure-ethylester 
• 79821-76-4 (S)-2-((ethoxycarbonyl)amino)-1-(2-methoxyphenyl)-1-propanone 
• 183140-31-0 ethyl (4S)-4-ethoxycarbonylamino-3-oxo-2-triphenylphosphoranylidenepentanoate 
• 568550-19-6 (S)-N-carbethoxy-2-amino-1-(4-fluorophenyl)propanone 
• 136114-32-4 [(S)-1-Methyl-2-oxo-2-(2,4,6-trimethyl-phenyl)-ethyl]-carbamic acid ethyl ester 
• 136114-34-6 [(S)-2-Hydroxy-2-(2-methoxy-phenyl)-1-methyl-ethyl]-carbamic acid ethyl ester 
• 136114-33-5 [(S)-2-Hydroxy-1-methyl-2-(2,4,6-trimethyl-phenyl)-ethyl]-carbamic acid ethyl ester 

Relevant academic research and scientific papers

A Straightforward and High-Yielding Synthesis of 1,2,4-Oxadiazoles from Chiral N-Protected α-Amino Acids and Amidoximes in Acetone-Water: An Eco-Friendly Approach

A straightforward and high-yielding methodology for the synthesis of a high structural diversity of 1,2,4-oxadiazoles from different chiral N-protected α-amino acids and amidoximes under microwave (MW) irradiation is described herein. This greener approac

Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters

Background and Purpose: 4-Methyl-N-methylcathinone (mephedrone) is a synthetic stimulant that acts as a substrate-type releaser at transporters for dopamine (DAT), noradrenaline (NET) and 5-HT (SERT). Upon systemic administration, mephedrone is metabolized to several phase I compounds: the N-demethylated metabolite, 4-methylcathinone (nor-mephedrone); the ring-hydroxylated metabolite, 4-hydroxytolylmephedrone (4-OH-mephedrone); and the reduced keto-metabolite, dihydromephedrone. Experimental Approach: We used in vitro assays to compare the effects of mephedrone and synthetically prepared metabolites on transporter-mediated uptake and release in HEK293 cells expressing human monoamine transporters and in rat brain synaptosomes. In vivo microdialysis was employed to examine the effects of i.v. metabolite injection (1 and 3?mg·kg?1) on extracellular dopamine and 5-HT levels in rat nucleus accumbens. Key Results: In cells expressing transporters, mephedrone and its metabolites inhibited uptake, although dihydromephedrone was weak overall. In cells and synaptosomes, nor-mephedrone and 4-OH-mephedrone served as transportable substrates, inducing release via monoamine transporters. When administered to rats, mephedrone and nor-mephedrone produced elevations in extracellular dopamine and 5-HT, whereas 4-OH-mephedrone did not. Mephedrone and nor-mephedrone, but not 4-OH-mephedrone, induced locomotor activity. Conclusions and Implications: Our results demonstrate that phase I metabolites of mephedrone are transporter substrates (i.e. releasers) at DAT, NET and SERT, but dihydromephedrone is weak in this regard. When administered in vivo, nor-mephedrone increases extracellular dopamine and 5-HT in the brain whereas 4-OH-mephedrone does not, suggesting the latter metabolite does not penetrate the blood–brain barrier. Future studies should examine the pharmacokinetics of nor-mephedrone to determine its possible contribution to the in vivo effects produced by mephedrone.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.